Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension. Baxdrostat is a highly selective, oral, small molecule ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean ...

WILMINGTON, Del., July 14, 2025--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically ...

Meeting Coverage > ACC Novel Antihypertensive Stumbles Over Early-Phase Hurdle — Hopes remain high for baxdrostat despite trial's adherence problems by Crystal Phend, Contributing Editor ...

AstraZeneca’s experimental hypertension drug, baxdrostat, has achieved a major milestone. The company announced that its BaxHTN Phase III trial met both primary and secondary endpoints, demonstrating ...

Results showed baxdrostat met its primary endpoint and achieved statistically significant placebo-adjusted reduction in systolic blood pressure, including 11 mmHg (p-value < 0.0001) at a dose of 2 mg.

--CinCor Pharma, Inc. today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of an oral presentation at the upcoming 29 th ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension. Baxdrostat is a highly selective, oral, small molecule ...

Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI) that targets the hormone driving elevated blood pressure and increased cardiovascular and renal risk.